NYSE:MSTX

Mast Therapeutics Stock Insider Trading

*Your capital is at risk

$15.54

+0 (+0%)

At Close: Jun 08, 2026

Mast Therapeutics Stock Insider Power

Based on the 45 latest insides trades, we have calculated the insider power to be negative at 0. In total, the insiders bought 9.3M and sold 0 MSTX shares in the last 45 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 45 transactions)	0
● Buy	9.3M shares
● Sell	0 shares
100% Buy Activity Negligible or No Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 11, 2015 Buy	Employee Stock Option (Right to Buy) A-Award	Emanuele Robert Martin Senior Vp, Development	Officer	291 500 Value: $145.8K
Jun 11, 2015 Buy	Stock Option (Right to Buy) A-Award	Ramsay David A Director	Director	82 963 Value: $41.5K
Jun 11, 2015 Buy	Employee Stock Option (Right to Buy) A-Award	Roberts Brandi Chief Financial Officer & SVP	C-Suite Officer	444 400 Value: $222.2K
Mar 27, 2015 Buy	Common Stock P-Purchase	Roberts Brandi Chief Financial Officer & SVP	C-Suite Officer	18 000 Value: $9K
Mar 26, 2015 Buy	Common Stock P-Purchase	Roberts Brandi Chief Financial Officer & SVP	C-Suite Officer	20 000 Value: $10.0K
Jan 02, 2015 Buy	Stock Option (Right to Buy) A-Award	Emanuele Robert Martin Senior Vp, Development	Officer	500 250 Value: $290.1K
Jan 02, 2015 Buy	Stock Option (Right to Buy) A-Award	Roberts Brandi Chief Financial Officer & SVP	C-Suite Officer	722 800 Value: $419.2K
Jun 19, 2014 Buy	Stock Option (Right to Buy) A-Award	Roberts Brandi Chief Financial Officer & SVP	C-Suite Officer	336 600 Value: $218.8K
Jun 19, 2014 Buy	Stock Option (Right to Buy) A-Award	Ramsay David A Director	Director	46 609 Value: $30.3K
Jun 19, 2014 Buy	Stock Option (Right to Buy) A-Award	Emanuele Robert Martin Senior Vp, Development	Officer	285 400 Value: $185.5K
Jun 19, 2014 Buy	Stock Option (Right to Buy) A-Award	Vetticaden Santosh Chief Medical Officer & SVP	Officer	529 300 Value: $344.0K
Jan 02, 2014 Buy	Employee Stock Option (Right to Buy) A-Award	Vetticaden Santosh Chief Medical Officer & SVP	Officer	295 100 Value: $138.7K
Jan 02, 2014 Buy	Employee Stock Option (Right to Buy) A-Award	Emanuele Robert Martin Senior Vp, Development	Officer	115 900 Value: $54.5K
Jan 02, 2014 Buy	Employee Stock Option (Right to Buy) A-Award	Roberts Brandi Chief Financial Officer & SVP	C-Suite Officer	101 200 Value: $47.6K
Jun 19, 2013 Buy	Employee Stock Option (Right to Buy) A-Award	Roberts Brandi Chief Financial Officer & SVP	C-Suite Officer	301 250 Value: $150.6K
Jun 19, 2013 Buy	Employee Stock Option (Right to Buy) A-Award	Culley Brian M CEO And Director	CEO / President	907 300 Value: $453.7K
Jun 19, 2013 Buy	Employee Stock Option (Right to Buy) A-Award	Vetticaden Santosh Chief Medical Officer & SVP	Officer	125 000 Value: $62.5K
Jun 19, 2013 Buy	Stock Option (Right to Buy) A-Award	Love Ted W Director	Director	62 451 Value: $31.2K
Jun 19, 2013 Buy	Stock Option (Right to Buy) A-Award	Ramsay David A Director	Director	62 451 Value: $31.2K
May 30, 2013 Buy	Common Stock A-Award	Emanuele Robert Martin Senior Vp, Development	Officer	52 543 Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT MAST THERAPEUTICS, INC

Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for serious or life-threatening diseases with significant unmet needs. The companys lead product candidate is MST-188 (vepoloxamer), an injection used for the treatment of sickle cell disease, arterial disease, and heart failure. It also develops AIR001, a sodium nitrite solution for intermittent inhalation via nebulizer, as well as for the treatment of hear...

Read Full Profile Here